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The induction ofstable mixed allogeneic chimerism as an approach to transplan-
tation tolerance has recently been reviewed in detail (1). Two murine models for
the induction of such stable mixed chimerism involve total lymphoid irradiation
(TLI)' followed by infusion of allogeneic bone marrow (BM) (2) and lethal whole
body irradiation(WBI)followed by reconstitution with amixture ofTcell-depleted
(TCD) syngeneic and allogeneicBM (3, 4). Both ofthese regimens have been shown
to produce long-term mixed lymphohematopoietic chimerism and specific tolerance
todonorskin grafts, and in bothcases the resultingmixed chimeras have been shown
to be otherwise immunocompetent (4, 5).
One major drawback, however, to the clinical use of these approaches to the in-
duction of transplant tolerance has been the excessive toxicity of both irradiation
regimens required for the establishment of mixed chimeras. The recent report by
Cobbold et al. (6) that treatment ofmice with anti-T cell mAbs could promote al-
logeneic marrowengraftment was therefore ofboth theoreticalandpractical interest.
However, the chimerism achieved by these authors was transient unless relatively
high doses of whole body irradiation (600 and 850 rad) were administered in addi-
tion to the mAb treatment. Animals prepared in this fashion demonstrated fully
allogeneic reconstitution rather than mixed chimerism (6), and the immunocompe-
tence of these chimeras was not examined.
In present study we have attempted to reproduce and extend these results. We
have found that treatment ofmice with antiT cell mAbs leads to profound periph-
eral T cell depletion but fails to deplete mature T cells from the thymus . We there-
fore reasoned that the requirement for high dose whole body irradiation to achieve
stable chimerism in the studies by Cobbold et al. might have been due to the need
forremovalofmature thymic T cells. Whilethymectomy might overcome thisproblem,
it would also leave an animal without thymic stromal elements capable ofeducating
newT cellsfrom host anddonorstem cell populations. We thereforeattempted selective
thymic irradiation (TI) todeplete thymic Tcells. We report here thatthisprocedure
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' Abbreviations used in this paper . BM, bone marrow, BMT, bone marrow transplantation; GVHD, graft-
versus-host disease; RAMB, rabbit anti-mouse brain; TCD, T cell-depleted; TI, thymic irradiation;
TLI, total lymphoid irradiation; WBI, whole body irradiation.
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permits stable mixed allogeneic chimerism to develop in animals following a low
dose (300 rod) of whole body irradiation and mAb treatment.
Materials and Methods
Animals.
￿
8-16-wk-old mice of strains C57BL/IOSn (1310), C57BL/6 (136), B10.D2/nSn
(BIO.D2), and B10.BR/SgSn (BIO.BR) were purchased from The Jackson Laboratory, Bar
Harbor, ME. B6.PLThy-1" (B6Thy-1.1) mice (7) were obtained from the Frederick Cancer
Research Facility, Frederick, MD. All mice were maintained in a specific pathogen-free envi-
ronment.
ExperimentalProtocol.
￿
Thetwo mAbs used for in vivo treatment were GK1.5, a rat anti-mouse
CD4 mAb (8), and 2 .43, a rat anti-mouse CD8 mAb (9). Both GK1.5 and 2.43 hybridoma
lines were obtained from the American Type Culture Collection, Rockville, MD. These mAbs
were purified from ascites prepared in nude mice by 50% ammonium sulfate precipitation
followed by filtration on an Ultrogel AcA 34 column (IBF Biotechnics, Sevage, MD). Recip-
ient 1310 or B6 mice were treated with both purified mAbs (500 1Ag each) by intraperitoneal
injection 5-6 d before bone marrow transplantation (BMT). Control animals were treated
with PBS or with 1 mg of purified rat IgG (Organon Teknika Corp., West Chester, PA). On
the day of BMT, WBI (120 rod per minute) was administered using a''7Cs source and selec-
tive thymic irradiation (63 rod per minute) was performed using a therapeutic x-ray machine
(Philips Electronic Instruments, Inc., Mahwah, NJ). For thymic irradiation, mice were anesthe-
tized and positioned under a lead shield from which a hole had been cut in order to selectively
irradiate the region of the thymus. Donor B10.D2 or B6Thy-1.1 bone marrow was harvested
from the long bones as previously described (4) and was administered intravenously in a 1-ml
volume (10-15 x 106 cells). T cell depletion of B6Thy-1.1 BM cells was accomplished by treat-
ment with rabbit anti-mouse brain (RAMS) serum and guinea pig complement (10) before
administration to B6 recipients.
T Cell Depletion Analysis.
￿
Mice treated with mAbs alone were tested for the level of T cell
depletion by flow cytometry analysis on a FRCS II (Becton Dickinson & Co., Mountain View,
CA). 5 d after mAb treatment PBMC, spleen cells, and thymocytes were stained directly
with fluoresceinated antiThy-1.2 (Becton Dickinson Immunocytometry System, Mountain
View, CA) or indirectly with GK1.5 (0.5 ttg) plus 2.43 (0.5 pg) followed by fluoresceinated
mouse mAbs to rat Ig light chain (MAR18.5, Becton Dickinson & Co.).
Characterization ofChimeras.
￿
Transplanted mice were tested for the level ofallogeneic donor
T and nonT cells by two-color flow cytometry analysis as previously described (11). PBL
were stained with fluoresceinated antiThy-1.2 (green) and with biotinylated anti-H-2"(34-
2-12) (12) antibodies plus Texas Red Streptavidin (Bethesda Research Laboratories, Gaithers-
burg, MD) (red). Two-color data were displayed as contour diagrams with logarithmically
increasing intensities of green (FITC) fluorescence plotted on the x axis versus logarithmi-
cally increasing intensities of red (Texas-Red) fluorescence on they axis. Chimerism in the
Thy-1 congenic model (136Thyl.I-136) was determined by staining donor T cells with fluoresce-
inated antiThy-1.1 (Bioproducts for Science INC., Indianapolis, IN) (green) and host T cells
with biotinylated antiThy-1.2 plus Texas Red Streptavidin (red). Nonspecific staining was
assessed with irrelevant mAbs (fluoresceinated or biotinylated anti-Leu-4; Becton Dickinson
& Co.).
Evaluation of Specific Tolerance.
￿
Specific tolerance was assessed by comparing the survival
time of donor skin grafts (1310.132) with the survival time ofthird-party skin grafts (B10.BR).
Skin grafts were performed as previously described (4) between 6-8 wk after BMT by the
method of Billingham (13), using full-thickness tail skin grafted to the lateral thorax . Grafts
were examined daily in the first month and then every 2 d for signs of rejection. Rejection
was considered complete when no viable tissue was detectable by visual inspection .
Results
Minimal Host Conditioning Required to Attain Allogeneic Engraftment.
￿
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traperitoneal administration of anti-T cell mAbs. A time course study showed that
maximal depletion ofT cells in the peripheral tissues after administration of 500
!Ag each ofGK1.5 and 2.43 occurred within 5 d after treatment (Table I). However,
this same mAb treatment failed to depleteTcellsfrom the thymus . The totalnumber
of thymic cells did not significantly change, and thymic T cells were found to be
coated with the injected rat antibodies but not eliminated, as indicated by staining
with theMARFITC reagent . As shown in Table II A, group 1, this treatment regimen
was found to be inadequate to permit engraftment of allogeneic BM, as donor cell
chimerism was not detectable 2 wk after BMT .
Two additional treatments were therefore added to the mAbs in order to deter-
mine the minimal requirements for obtaining detectable chimerism 2wk after ad-
ministration of allogeneic bone marrow : (a) Administration of a low dose of WBI
(300 rad), the lowest dose previously shown to permit transient engraftment after
mAb treatment (6) ; and (b) administration of thymic irradiation to a total dose of
1,000 rad, thedose ofWBI previously used for production of stable mixed allogeneic
chimeras in this laboratory (4) . The results of these studies are shown in Table II .
As seen from these data, none of the three conditioning treatments alone (Table
II A, groups 1-3) was sufficient to achieve chimerism in animals examined 2 wk
after BM administration. Of the three possible combinations of these treatments
taken two at a time, only mAbs plus the 300-rad WBI were sufficient to produce
chimerism (Table II A, group 6) . However, as shown for one representative animal
in Fig. 1, this chimerism was transient, with subsequent loss of detectable donor
cells and without induction of tolerance. 3 of 3 such animals grafted with donor
skin rejected their grafts within 14 d, as did unmanipulated animals. On the other
hand, more consistent stable engraftment was achieved by addition of700 rad selec-
tive thymic irradiation to themAb and 300 radWBI treatments (Table II A, group
7) . In the first set of experiments, 4 of 10 animals treated with this regimen devel-
oped long-term, stable mixed chimerism, as shown for one representative animal
in Fig. 2 . T cells ofboth host and donor origin developed by day 32 and chimerism
in bothTand non-T cells persisted >150 d. Stable mixed chimerism was accompa-
nied by induction of long-term tolerance to donor B10.D2 skin grafts (grafted 39
TABLE I
T Cell Level 5 d after In Vivo Administration of GKI.5 plus 2.43
Percent positive cells
Fluoresceinated mouse anti-rat mAb .
I Control mice were treated 5 d before analysis with PBS or 1 mg nonspecific rat IgG .
4 Individual mice were injected 5 d before analysis with 500 Ftg each of GK1 .5 (anti-CD4)
and 2.43 (anti-CD8) .
In vivo
Cell source : Blood Spleen
Anti-
Thymus
GKI .5 + 2.43
treatment Staining mAbs : Thy-1 .2-FITC + MAR-FITC' MAR-FITC
PBSI 28 21 99 2
Rat IgGT 31 22 99 2
GK1 .5 + 2.43§ 4 7 98 43
GK1 .5 + 2.434 2 4 97 70496
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TABLE II
Host Preparative Regimens Attempted for Allogeneic BM Engraftment
1310 mice receiving the different conditioning regimens were infused with 15
x 106 unmanipulated B10.D2 BM cells. Chimerism in peripheral blood was
analyzed by flow cytometry using staining with anti-donor H-2 antibodies
(34-2-12, anti-Dd). Transplanted animals were grafted between 6-8 wk after
BMT with donor skin grafts (1310.132).
(A) Data represent summary of several experiments.
(B) Data from a single experiment performed after improved thymic irradia-
tion protocol.
Intraperitoneal injection of GK1 .5 (anti-CD4) plus 2.43 (anti-CD8), 5-6 d
before BMT. WBI and TI administered on day of BMT.
All animals with long-term survival of donor skin grafts demonstrated stable
mixed chimerism (>150 d).
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staining with antiThy-1.2 mAb,
staining all T cells (green flu-
orescence, horizontal axis), and
anti-D' mAb, staining all cells
of B10.D2 donor origin (red
fluorescence, vertical axis) are
shown . Cuts ofcontour plotson
DAY 91
￿
DAY 156
￿
the x-axis were done such that
they included <0.2% of cells
staining with irrelevant anti-
bodies . Cuts ofcontour plotson
the y-axis were done such that
they included 97-99% of posi-
tive control cells (B10.D2) stain-
ing with anti-D' and <2% of
1
￿
2
￿
3
￿
1
￿
2
￿
3
￿
negative cells (B10) . In all cases
ANTI-THY 1 .2
￿
staining with irrelevant mAb
LOG, GREEN FLUORESCENCE
￿
wasdone, and was less than or
equal to staining of 1310 cells.
d after BMT), which remained intact for >100 d . Control 1310 animals that did not
receive B10.D2 BM rejected such grafts within 14 d (data not shown) .
In an attempt to increase the incidence of stable mixed chimerism achieved by
this combination treatment regimen (i.e ., mAbs, 300-rad WBI, and 700 rad thymic
irradiation), a more reliable system for assuring exposure ofthymus to irradiation
was devised using chest markings . After such treatment, as shown in Table II B,
10 of 10 animals developed stable mixed chimerism persisting >150 d . Stable
chimerism in each case was associated with tolerance to donor skin grafts . In this
experiment, 4 of 10 control animals without thymic irradiation also developed per-
manent chimerism and long-term survival of donor skin grafts (Table II B) . In con-
trast to the first set of experiments, however, the rejection of donor cells in most
of the nontolerized mice was slow and proceeded after donor skin grafts were al-
ready rejected . Thus, in all experiments thymic irradiation markedly increased the
percentage of animals developing stable chimerism and tolerance . Pooling the results
of all experiments, engraftment increased from 30°Jo (4/13) without TI to 70% (14/20)
with TI, which is statistically significant (p < 0.05 by X2 analysis) .
Specificity of Transplant Tolerance. The specificity of tolerance in the mixed chimeric
animals was determined by comparing their responses to donor skin grafts (1310.D2)
and to third-party skin grafts (B10.13R) . All chimeras that demonstrated long-term
survival of donor (B10 .D2) skin grafts were fully reactive to third-party (B10.BR)
skin grafts (as shown in Fig. 3 for animals in Table 11 B), rejecting such grafts at498
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the same time as did control animals not receiving B10.D2 BM (data not shown).
Such long-term, specific tolerance was found exclusively in animals with stable mixed
chimerism.
Host Survival without Bone Marrow Administration.
￿
As demonstrated in Fig. 4, the
combination host conditioning regimen that produced long-term, mixed allogeneic
chimerism was in itself nonlethal, in contrast to the WBI regimen previously used
to achieve mixed allogeneic chimerism without mAb treatment (4, 14). Animals treated
by the combined protocol but not receiving marrow remained healthy and gained
weight at a rate similar to untreated control animals.
Minimal Host Conditioningfor Syngeneic BM Engraftment.
￿
In an attempt to deter-
mine whether 300 rad WBI was required in order to over come residual host al-
loresistance after mAb treatment, or to create "room" for engraftment of injected
BM, we studied the minimal conditions required for BM engraftment in the ab-
sence of alloreactivity. For this purpose, Thy-1 congenic mice (B6Thy-1.1-"B6) that
differ only in the allelic form of Thy-1 antigen on T cells were used . Thy-1 alleles
are not known to generate transplant reactions in mice (Mobraaten, L. E., TheJackson
Laboratory, Bar Harbor, ME; personal communication). In this experiment T cells
were depleted from donor marrow so that only T cell chimerism arising from stem
cells or precursor cells in the marrow would be detected . As shown in Table III,
conditioning of syngeneic hosts (B6) with 300-rad WBI was necessary and sufficient
for engraftment of T cell depleted (TCD) B6Thy-1.1 BM . In contrast, treatment
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FIGURE 3.
￿
Specific tolerance to donor alloantigens in
mixed chimeric animals. 1310 (H-26)mice were treated
with mAbs GK1.5 (anti-CD4) plus 2.43(anti-CD8) and
300-rad WBI with (A, A) or without (", O) 700-rad
thymic irradiation. Pretreated animals were infusedwith
15 x 106 B10.D2 (H-2d) BM cells and received donor
B10.D2 (H-2d) skin grafts (A, ") and third-party
B10.BR (H-2k) skin grafts (A, O) 7 wk later.
FIGURE 4. Mice treated with the complete
regimen without BM transplant demonstrated
long-termsurvival. Survival of 1310 mice (4)that
received mAbs, 300-rad WBI and 700-rad thymic
irradiation (A)without BM iscomparedwith the
survival oflethally irradiated (1,025 rad) mice (6)
not receiving BM (O).SHARABI AND SACHS
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TABLE III
Minimal Host Conditioning for BM Engraftment in
Thy-1 Congenic Strain Combination
B6 recipients (two to three mice in each group), either untreated or treated
with mAbs and/or 300-rod WBI, were infused with 107 TCD B6-Thy-1 .1 BM .
T cell chimerism was assessed 4 mo afterBMT by staining with fluoresceinat-
ed anti-Thy-1 .1 and biotinylated anti-Thy-1 .2 .
* B6 recipients were injected with 500 ug of both GK 1 .5 (anti-CD4) and 2.43
(anti-CD8) mAbs 5 d beforeBMT . 300-rod WBI was administered on the day
of BMT .
1 No detectable staining by fluoresceinated anti-Thy-1 .1 above background stain-
ing of negative control animal (B6) cells .
with anti-CD4 plus anti-CD8 alone did not permit engraftment ofTCDB6Thy-1 .1
marrow. The possibility that mAbs prevented engraftment by depleting donor T
cells (either residual T cells in the BM inocula or newly developing donor T cells
in thehost)wasunlikely, since administration ofmAbs with 300-roddid notprevent
engraftment . Thus 300 rod WBI was essential for engraftment even in a system in
which rejection of donor cells by the host was unlikely.
Discussion
The use ofmAbs directed againstT cell subsets in vivo represents a powerful ad-
dition to the preparative regimens now available forthe induction of immunological
nonresponsiveness . One major limitation of this approach, however, is thepotential
for relevant cells to escape destruction either because they are inaccessible to the
administered antibodies, or because they arecoated by theantibodies but notdepleted .
Possible causes for failure to deplete coated target cells include modulation of sur-
face antigen and/or inaccessibility of the cells to mechanisms leading to elimination
of coated cells in vivo. Our findings suggest that the previous failure by Cobbold
et al . toachieve permanentallogeneic engraftment after300-rod WBI, in vivo anti-T
cell mAb treatment, and administration of allogeneic bone marrow (6) may have
been due to sparing ofT cells in the thymus . The present studies demonstrate that
anti-CD4 plus anti-CD8 mAbs lead to effective depletion of peripheral blood and
spleenT cells by day 5, but that thymicT cells are only coated with mAbs and not
eliminated . This observation is consistent with previous reports demonstrating the
inability of anti-CD4 (15) or antiThy-1.1 (16) to eliminate thymocytes .
The addition of 700 rod selective thymic irradiation to the preparative regimen
was attempted in order to raise the total dose of thymic irradiation to 1,000 rod,
adose that permits allogeneic engraftment when administered as WBI withoutmAb
treatment (14) . This additional radiation led to long-term, stable chimerism and
specific tolerance in 4 of 10 animals in the first set of experiments and in 10 of 10
animals for which the improved TI protocol was applied. These data strongly sug-
Host
mAbs
conditioning*
300 rod WBI
Percent donor Thy-1 .1 * cells
in peripheral blood T cells
- - 01
+ - 0
- + 10-34
+ + 36-51500
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gest that the transience of engraftment in previous protocols was due to the inability
to eliminate thymic T cellsby treatment with mAbs. The importance of eliminating
T cells from the thymus has also been demonstrated in the TLI model (2), in which
the thymus as well as the peripherallymphoid tissues must be included in the irradi-
ation field in order to achieve the full immunosuppressive effect of the irradiation
treatment.
In all experiments in the present study, thymic irradiation increased the incidence
of stable chimerism and transplantation tolerance. In one experiment, however, 4070
of animals not receiving thymic irradiation also developed specific tolerance. This
difference between experiments may have been due to age-related changes in the
state of thymic maturation. Investigations ofthe effects of thymic irradiation in animals
of different ages are now in progress.
It is also clear from our data that mAb treatment plus thymic irradiation alone
was insufficient to permit engraftment. Despite the fact that the dose of WBI used
(300 rad) was far too low to ablate host resistance to alloengraftment by itself (Table
II), this dose appeared to be sufficient to allow alloengraftment to proceed when
combined with mAb treatment and thymic irradiation. This dose of WBI was also
found to be essential for the engraftment of BM from otherwise syngeneic, Thy-1
congenic donors, from which BM did not engraft in unmanipulated hosts or after
in vivo mAb treatment alone. These data are consistent with the hypothesis that
"room" must be made for engraftment of self-renewing cell populations in order for
chimerism to be achieved . We cannot rule out the possibility that in the allogeneic
model, 300-rad WBI is also necessary to deplete a residual host cell population respon-
sible for host resistance.
Using this preparative regimen there appeared to be no GVHD despite the ad-
ministration of nonTCD allogeneic BM . This might be due to elimination of ma-
ture T cells from the donor BM inocula by residual anti-CD4 and anti-CD8 mAbs
that persist in the host blood for more than 2 wk after treatment (data not shown).
Such elimination ofdonor T cellswould not be expected to impair engraftment since
TCD allogeneic BM also engrafts using the preparative regimen described here (17).
Animals prepared by the combined regimen (mAb treatment, 300-rad WBI, and
700-rad thymic irradiation) demonstrated mixed chimerism rather than the fully
allogeneic reconstitution achieved with the higher dose (600 or 850 rad) ofWBI and
mAb treatment used by Cobbold et al . (6). Mixed allogeneic chimerism as an ap-
proach to the induction of donor specific transplantation tolerance has practical and
theoretical advantages over fully allogeneic chimerism (1). The autologous elements
provide a safeguard against aplasia in case of alloengraftment failure, as demon-
strated in this study by the excellent survival of mice receiving the preparative regimen
without allogeneic BM. In addition, autologous cells provide a source of host type
accessory cells for presentation ofantigen to new T cells educated in the host thymus,
thus contributing to the immunocompetence of the chimeric animals (3, 4).
Summary
The use of allogeneic bone marrow transplantation as a meansof inducing donor-
specific tolerance across MHC barriers could provide an immunologically specific
conditioning regimen for organ transplantation. However, a major limitation to this
approach is the toxicity of whole body irradiation as currently used to abrogate hostresistance and permit marrow engraftment . The present study describes method-
ology for abrogating host resistance and permitting marrow engraftment without
lethal irradiation. Our preparative protocol involves administration ofanti-CD4 and
anti-CD8 mAbs in vivo, 300-rad WBI, 700-rad thymic irradiation, and unmanipu-
lated fully MHC-disparate bone marrow. B10 mice prepared by this regimen devel-
oped stable mixed lymphohematopoetic chimerism without any clinical evidence
of graft-vs.-host disease. Engraftment was accompanied by induction of specific toler-
ance to donor skin grafts (Bl0.D2), while third-party skin grafts (B10.BR) were
promptly rejected. Mice treated with the complete regimen without bone marrow
transplantation appeared healthy and enjoyed long-term survival . This study there-
fore demonstrates that stable mixed chimerism with donor-specific tolerance can
be induced across an MHC barrier after a nonlethal preparative regimen, without
clinical GVHD and without the risk of aplasia.
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